Table 3. Comparison of anticoagulation status between males and females.
| Female (n=2,308) | Male (n=3,966) | p | |||
|---|---|---|---|---|---|
| Any anticoagulant | 1,771 (76.7) | 2,564 (64.6) | <0.001 | ||
| Warfarin | 344 (14.9) | 748 (18.9) | <0.001 | ||
| NOAC | 1,427 (61.8) | 1,818 (45.8) | <0.001 | ||
| Dabigatran | 331 (14.3) | 541 (13.6) | 0.462 | ||
| Rivaroxaban | 332 (14.4) | 439 (11.1) | <0.001 | ||
| Apixaban | 561 (24.3) | 637 (16.1) | <0.001 | ||
| Edoxaban | 204 (8.8) | 203 (5.1) | <0.001 | ||
| NOAC dosing adequacy* | <0.001 | ||||
| Guideline-recommended dose | 515 (36.6) | 772 (43.0) | |||
| Insufficient dose | 867 (61.5) | 1,011 (56.3) | |||
| Over dose | 27 (1.9) | 13 (0.7) | |||
| Anticoagulation rate for patients with | |||||
| CHA2DS2-VA score=1† | 335 (70.2) | 429 (44.1) | <0.001 | ||
| Warfarin | 63 (13.2) | 197 (20.2) | 0.001 | ||
| NOAC | 272 (57.0) | 232 (23.8) | <0.001 | ||
| CHA2DS2-VA score=2 or higher† | 1,361 (85.7) | 1,952 (81.9) | 0.002 | ||
| Warfarin | 243 (15.3) | 469 (19.7) | <0.001 | ||
| NOAC | 1,118 (70.4) | 1,485 (62.3) | <0.001 | ||
| CHADS2 score=1 | 544 (74.3) | 684 (53.3) | <0.001 | ||
| CHADS2 score=2 or higher | 1,092 (86.1) | 1,629 (81.7) | 0.001 | ||
| Antiplatelets | |||||
| Aspirin | 318 (14.6) | 828 (21.5) | <0.001 | ||
| Clopidogrel | 111 (5.1) | 298 (7.7) | <0.001 | ||
NOAC = non-vitamin K antagonist oral anticoagulant.
*Information about the NOAC dosage was missing in 28 female and 22 male patients; †Excluding points for sex category.